Laboratory characteristics of the study cohort
| Patient no. . | aCL . | Anti-β2GPI . | aPS/PT . | aPT-A . |
|---|---|---|---|---|
| P1 | + | + | +++ | + |
| P3 | ++ | ++++ | ++++ | +++ |
| P4 | ++ | ++ | ++++ | + |
| P6 | +++ | +++ | +++ | - |
| P7 | + | + | ++++ | ++++ |
| P8 | +++ | +++ | ++ | - |
| P9 | ++ | + | ++++ | ++++ |
| P10 | + | +++ | +++ | - |
| P11 | + | ++ | + | - |
| P12 | ++ | +++ | + | - |
| P13 | +++ | ++++ | +++ | ++ |
| P14 | +++ | +++ | ++++ | + |
| P15 | +++ | +++ | + | - |
| P16 | + | + | +++ | - |
| P17 | +++ | ++++ | ++++ | - |
| P18 | +++ | +++ | + | - |
| P19 | + | ++ | +++ | - |
| P20 | + | + | +++ | + |
| P21 | ++ | ++ | ++++ | + |
| P23 | ++ | + | ++++ | +++ |
| P24 | ++ | +++ | ++++ | + |
| P25 | + | ++ | +++ | - |
| P26 | +++ | ++++ | ++++ | + |
| P27 | + | + | ++++ | + |
| Patient no. . | aCL . | Anti-β2GPI . | aPS/PT . | aPT-A . |
|---|---|---|---|---|
| P1 | + | + | +++ | + |
| P3 | ++ | ++++ | ++++ | +++ |
| P4 | ++ | ++ | ++++ | + |
| P6 | +++ | +++ | +++ | - |
| P7 | + | + | ++++ | ++++ |
| P8 | +++ | +++ | ++ | - |
| P9 | ++ | + | ++++ | ++++ |
| P10 | + | +++ | +++ | - |
| P11 | + | ++ | + | - |
| P12 | ++ | +++ | + | - |
| P13 | +++ | ++++ | +++ | ++ |
| P14 | +++ | +++ | ++++ | + |
| P15 | +++ | +++ | + | - |
| P16 | + | + | +++ | - |
| P17 | +++ | ++++ | ++++ | - |
| P18 | +++ | +++ | + | - |
| P19 | + | ++ | +++ | - |
| P20 | + | + | +++ | + |
| P21 | ++ | ++ | ++++ | + |
| P23 | ++ | + | ++++ | +++ |
| P24 | ++ | +++ | ++++ | + |
| P25 | + | ++ | +++ | - |
| P26 | +++ | ++++ | ++++ | + |
| P27 | + | + | ++++ | + |
Optical density values at 450 nm for aCL, aβ2GPI, aPS/PT, and aPT-A. All patients showed lupus anticoagulant, measured as prolongation of the clotting time.3,29 P2, P5, and P22 had levels of aPS/PT below the cutoff and were therefore omitted. Scoring system for the ELISA assays: + = from 0.25 to 0.5; ++ = from 0.5 to 1.0; +++ = from 1.0 to 2.0; ++++ = from 2.0 to maximum. White = Group A; Blue = Group B.